AIDS Treatment News logo      

September 4, 2009

d4T dose reduction does not result in poorer treatment outcomes in South African patients

"The use of a reduced dose of d4T (stavudine), as recommended by the World Health Organization, did not reduce the likelihood of viral load suppression after six months in a large cohort of South African patients, researchers from the Aurum Institute of Health Research report in the August 24th edition of AIDS.

"The use of d4T in first-line treatment has been phased out in the developed world due to toxicity, but in developing countries fixed-dose combinations containing d4T are still widely used due to the drug’s low cost compared to tenofovir or abacavir. In South Africa d4T remains a staple component of first-line treatment in the public health system, despite widespread calls for its use to be phased out."

Read more in Aidsmap, September 4, 2009.

0 comments: